Study
Bryan Johnson reports advanced meibomian gland dysfunction and a 4-treatment eye protocol
NEW BIOMARKER UPDATE / EXPERIMENT: Johnson reports advanced meibomian gland dysfunction, tear production under 10 mm in 5 minutes in both eyes, gland dropout, and a combined IPL/RF/probing/LLLT protocol; he reports 30% imaging improvement but cannot assign causality.
Summary What is this four-part eye treatment protocol supposed to do? Show / hide ↓
This report describes advanced meibomian gland dysfunction, meaning the oil-producing glands in the eyelids are not working properly. Tear production was under 10 mm in five minutes in both eyes, and some glands had disappeared, a finding called gland dropout. The protocol combined IPL, pulsed light treatment; RF, radiofrequency heating; gland probing to open blocked glands; and LLLT, low-level light therapy. Eye imaging reportedly improved by 30%, but the report cannot show which treatment caused the change or whether it would work for others.
What this means for you: This is an individual treatment report, not strong proof that the four-part protocol works. There is not enough evidence to recommend buying or copying it.
weak evidenceOn 18 August 2026, Bryan Johnson reported a new eye diagnosis and treatment series. He says an ophthalmologist, Dr Amir Moarefi, found advanced meibomian gland dysfunction (MGD), tear production under 10 mm in 5 minutes in both eyes, and substantial meibomian-gland dropout on infrared meibography. He links the condition to evaporative dry eye and concurrent aqueous deficiency. The intervention bundle combines intense pulsed light, radiofrequency, manual gland expression, intraductal probing, and 630 nm low-level light therapy. He also reports warm compresses, preservative-free and lipid-replacement drops, prescription anti-inflammatory drops, a compounded azithromycin spray, moisture-chamber glasses, tear stimulation, omega-3, and lutein. Johnson says imaging showed a 30% improvement in gland function, with less irritation and less resistance during probing. The design has no control condition, no prespecified primary endpoint, no independent assessor, and several treatments started together. He therefore cannot identify which component produced the change. The post labels intraductal probing as experimental and describes future plans involving androgen, growth-factor, or organoid approaches that have not been tested in humans. This is a detailed n=1 medical report, not evidence that the combined protocol reverses gland loss or dry eye in other people. The reported tear values and imaging results need clinical records and repeat measurements for independent assessment.
Given that I did four therapies at the same time: IPL, RF, probing, and low level light therapy, I can’t determine which therapy did what.
No independent human RCT or meta-analysis on this exact combination was found in the weekly search. The post itself states that the science on intraductal probing is not settled. No ingredient evidence-grade upgrade follows.
From this page back to the goal it moves.
Cited by
2 encyclopedia entries reference this study.